Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

Utz O. Krug, MD, Maria Cristina Sauerland, PhD, Bernhard J Woermann, MD, Wolfgang Berdel, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 1056.

https://doi.org/10.1182/blood.V114.22.1056.1056

Published: 2009

Journal Articles

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

Friederike Schneider, Annika Dufour, Tobias Benthaus, Stephanie Schneider, Gudrun Mellert, Evelyn Zellmeier, Stefan K Bohlander, Michael Unterhalt, Michaela Feuring-Buske, Christian Buske, Jan Braess, Maria Cristina Sauerland, Achim Heinecke, Wolfgang Berdel, Thomas Buechner, Bernhard Wörmann, Wolfgang Hiddemann, Karsten Spiekermann, Eva Hoster

Blood (2009) 114 (22): 2635.

https://doi.org/10.1182/blood.V114.22.2635.2635

Published: 2009

Journal Articles

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Christian Elling, Philipp Erben, MD, Christoph Walz, MD, Marie Frickenhaus, Mirle Schemionek, PhD, Martin Stehling, PhD, Hubert Serve, MD, PhD, Nick C.P. Cross, PhD, Wolfgang Berdel, MD, Carsten Mueller-Tidow, MD, Andreas Reiter, MD, Steffen Koschmieder, MD

Blood (2009) 114 (22): 767.

https://doi.org/10.1182/blood.V114.22.767.767

Published: 2009

Journal Articles

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Utz O. Krug, MD, Wolfgang Berdel, MD, Susanne Amler, Maria C. Sauerland, PhD, Bernhard Wörmann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 998.

https://doi.org/10.1182/blood.V114.22.998.998

Published: 2009

Journal Articles

Expression of Osteopontin in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Ruediger Liersch, MD, Michael Bayer, Christoph Biermann, Iris Appelmann, Christoph Schliemann, MD, Christian Schwoeppe, Torsten Kessler, MD, Carsten Mueller-Tidow, MD, Wolfgang Berdel, Rolf Mesters

Blood (2009) 114 (22): 4694.

https://doi.org/10.1182/blood.V114.22.4694.4694

Published: 2009

Journal Articles

Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003.

Markus Schaich, MD, Thomas Illmer, Walter E. Aulitzky, MD, Martin Bornhaeuser, Martin Griesshammer, Matthias Haenel, Anthony D. Ho, M.D., Ph.D., Hartmut Link, Andreas Neubauer, Norbert Schmitz, MD, Hubert Serve, MD, PhD, Christian Thiede, Eckhard Thiel, MD, PhD, Thomas Wagner, M.D., Hannes Wandt, MD, Wolfgang Berdel, Gerhard Ehninger on behalf of the Study Alliance Leukemia (SAL)

Blood (2008) 112 (11): 978.

https://doi.org/10.1182/blood.V112.11.978.978

Published: 2008

Journal Articles

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Jan Braess, MD, PhD, Karsten Spiekermann, MD, PhD, Christian Buske, MD, PhD, Peter Staib, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Andreas Gruneisen, MD, Christa Sauerland, PhD, Michael Unterhalt, MD, PhD, Michael Fiegl, MD, Bernhard Wormann, MD, PhD, Wolfgang Kern, MD, PhD, Achim Heinicke, PhD, Wolfgang Berdel, MD, PhD, Thomas Büchner, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2007) 110 (11): 295.

https://doi.org/10.1182/blood.V110.11.295.295

Published: 2007

Journal Articles

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

Jan Braess, MD, PhD, Peter Staib, MD, PhD, Wolf D. Ludwig, MD, PhD, Bernhard J. Wormann, MD, PhD, Andreas Reichle, MD, PhD, Wolfgang Berdel, MD, PhD, Thomas Buchner, MD, PhD, Andreas Gruneisen, MD, Christoph Schmid, MD, Christian Schmid, MD, PhD, Wolfgang Kern, MD, PhD, Karsten Spiekermann, MD, PhD, Michael Fiegl, MD, Michaela Feuring-Buske, MD, PhD, Stefan Bohlander, MD, PhD, Achim Heinicke, Christ Sauerland, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 1997.

https://doi.org/10.1182/blood.V108.11.1997.1997

Published: 2006

Journal Articles

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

Blood (2004) 104 (11): 871.

https://doi.org/10.1182/blood.V104.11.871.871

Published: 2004

Journal Articles

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, MD, PhD, Roswitha Forstpointner, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, PhD, Rudolf Schmits, MD, PhD, Bernd Metzner, MD, Marcel Reiser, MD, Eva Lengfelder, MD, PhD, Bernhard Woermann, MD, PhD, Hariett Harder, MD, Susanna Hegewisch-Becker, MD, PhD, Wolfgang Berdel, MD, PhD, Georg Hess, MD, Hartmut Eimermacher, MD, Ali Aldaoud, MD, Manfred Planker, MD, Reza Parwaresch, MD, PhD, Martin Dreyling, MD, PhD, Michael Unterhalt, MD

Blood (2004) 104 (11): 161.

https://doi.org/10.1182/blood.V104.11.161.161

Published: 2004

Journal Articles

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Wolfgang Kern, Torsten Haferlach, Claudia Schoch, Helmut Löffler, Winfried Gassmann, Achim Heinecke, Maria Christina Sauerland, Wolfgang Berdel, Thomas Büchner, Wolfgang Hiddemann

Blood (2003) 101 (1): 64–70.

https://doi.org/10.1182/blood-2002-02-0532

Published: 2003

NARROW

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Expression of Osteopontin in the Bone Marrow of Patients with Acute Myeloid Leukemia.

Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003.

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only